ClinicalTrials.gg
CompletedNCT04785638Updated Feb 13, 2023

An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries

A Phase 3 interventional study of INL-001 (bupivacaine hydrochloride) implant in Pain, Postoperative, Hernia, Ventral and Abdominoplasty, sponsored by Innocoll. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-13.

Sponsored by Innocoll · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
97th of 364
100 · median 70
Started
2021
with 30 others
Phase 3
42 of 364
2 open now
Registered
220th of 364
by date
Lead sponsor
6 of 364
Innocoll

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 97th largest by enrollment, is one of 31 that started in 2021, is one of 42 in phase 3, and was the 220th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL 001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty.

Read the detailed description

This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL-001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty. After a screening period, eligible patients will undergo study surgery under general anesthesia and have INL-001 implanted intraoperatively. Efficacy is also an exploratory measure in this study.

The study includes a screening period, an inpatient period (preoperative, intraoperative, postoperative) of approximately 5 days, and an outpatient follow-up period (up to 30 days after treatment). Posttreatment safety and/or efficacy assessments will be made throughout the study and as specifically scheduled through 96 hours posttreatment, on day 7 (telephone), on day 15 (clinic visit), and on day 30 (clinic visit). Unless the investigator determines further hospitalization is necessary, patients will be discharged approximately 96 hours posttreatment (inpatient day 5).

During the screening period, all patients will undergo eligibility and other screening and safety assessments. In addition, the investigator will administer the Pain Catastrophizing Scale (screening only) as an exploratory measure and the 15-item Quality of Recovery (QoR-15) questionnaire (baseline).

Adverse event and concomitant medication information, including use of rescue pain medication, will be collected throughout the study (inpatient and outpatient). Surgical wound healing/grading assessments and assessment for signs and symptoms potentially indicative of systemic bupivacaine toxicity will be made.

Blood samples for pharmacokinetic assessments will be collected from patients at multiple time points for the measurement of concentrations of bupivacaine in plasma.

After surgery, patient reports of pain intensity using an 11-point numeric pain rating scale (NPRS) will be recorded at multiple time points through 96 hours posttreatment. Patients will be permitted rescue medication (oral and/or intravenous) to manage breakthrough pain when it occurs. The QoR-15 questionnaire and Patient Global Assessment (for pain control) will be administered on an inpatient basis and on day 7. The Opioid Related Symptom Distress Scale will be administered on an inpatient basis.

03

Conditions studied

  • Pain, Postoperative
  • Hernia, Ventral
  • Abdominoplasty
  • Hysterectomy
  • Colectomy
  • Reduction Mammoplasty

Keywords

  • Pain
  • Analgesia
  • Postoperative
  • Hernia
  • Abdominoplasty
  • Tummy tuck
  • Hysterectomy
  • Colectomy
  • Bupivacaine
  • Postsurgical
  • Implant
  • Safety
  • Efficacy
  • Pharmacokinetic
  • Opioid
  • Nonopioid
  • Post-operative
  • Post-surgical
  • Surgery
  • Soft tissue
  • Open-label
  • Phase 3
  • Local anesthetic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a of 18-35 kg/m2.
  • Has a planned (nonemergency) open ventral hernia repair, abdominoplasty (with rectus sheath plication, in the opinion of the surgeon), open abdominal hysterectomy, laparoscopic-assisted colectomy, or reduction mammoplasty to be conducted using standard surgical technique under general anesthesia.
  • Has the ability and willingness to comply with all study procedures including being domiciled for at least 96 hours after surgery.
  • Is willing to use opioid analgesia, if needed.

Exclusion criteria

Exclusion Criteria:

  • Has a known to amide-type local anesthetics, fentanyl, morphine, oxycodone, acetaminophen, NSAIDs, or bovine products.
  • Is scheduled for other significant concurrent surgical procedures (eg, cholecystectomy or additional cosmetic procedures concurrent with abdominoplasty).
  • Has used an opioid analgesic on an extended daily basis (≥5 mg oral morphine equivalents per day for 3 or more days a week) within 4 weeks before surgery and/or chronically uses pain medication.
  • Has any chronic painful condition (eg, fibromyalgia), as determined by the investigator, that may confound the assessment of pain associated with the study surgery.
  • For open hernia repair, has open ventral hernia with primary suture repair and mesh placement requiring an incisional length greater than 12 cm.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    INL-001 (bupivacaine hydrochloride) implant

    INL-001 (bupivacaine hydrochloride) implant

    Combination Product: INL-001 (bupivacaine hydrochloride) implant

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability

    The primary objective of the study is to evaluate the safety and tolerability of the INL-001 implant in patients. Measured by frequency and incidents of adverse events.

    Time frame: Day 1 through Day 30

Secondary outcomes

  1. Cmax

    Maximum (peak) plasma concentration

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

  2. Tmax

    Time to maximum (peak) plasma concentration

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

  3. Tlag

    Lag-time

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

  4. t½ Terminal Half life

    Terminal Half life

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

  5. λz

    Terminal phase rate constant

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

  6. AUC

    Area under the plasma concentration-time curve from Time 0 to last time of last quantifiable plasma concentration (AUC0-last)

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

  7. AUC0-∞

    AUC from Time 0 to infinity

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours

Other outcomes

  1. SPI24

    Time-weighted sum of pain intensity from Time 0 through 24 hours (SPI24). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

    Time frame: 0 to 24 hours

  2. SPI48

    Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

    Time frame: 0 to 48 hours

  3. SPI72

    Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible" Minimum value would be "0" and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

    Time frame: 0 to 72 Hours

  4. Total use of opioid rescue analgesia

    Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome

    Time frame: 0 to 24 hours postoperatively

  5. Total use of opioid rescue analgesia

    Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome

    Time frame: 0 to 72 hours postoperatively

  6. Total use of opioid rescue analgesia

    Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome

    Time frame: 0 to 48 hours postoperatively

  7. Time to discharge from the postanesthesia care unit (PACU)

    Time to discharge from the PACU

    Time frame: Immediately after the intervention/procedure/surgery

  8. Opioid-related Symptom Distress Scale (OR-SDS)

    The OR-SDS is a measurement tool to assess patient experience following opioid use in the postoperative setting.

    Time frame: 24, 48, 72, and 96 hours posttreatment

  9. 15-item Quality of Recovery (QoR-15) Questionnaire

    The 15-item Quality of Recovery (QoR-15) Questionnaire s a surgical recovery assessment tool. The QoR-15 assesses postsurgical recovery from the patient's perspective and incorporates all 5 dimensions of health patient support, comfort, emotions, physical independence, and pain. Investigator judgement will be used to determine if a positive finding on the QoR-15 is clinically significant and reportable as an adverse event.

    Time frame: 24, 48, 72, and 96 hours, and day 7 posttreatment

  10. Patient Global Assessment (PGA) as Related to Postoperative Pain

    The PGA will be administered by study staff who ask patients to rate "how well your pain has been controlled during the study" on a 5 point nominal scale: 0-poor, 1-fair, 2-good, 3-ery good, or 4-excellent.

    Time frame: 24, 48, 72, and 96 hours, and day 7 posttreatment

07

Study locations

8 sites
  • North Alabama Medical Center
    Florence, Alabama 35630, United States
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Lotus Clinical Research
    Pasadena, California 91105, United States
  • Midwest Clinical Research
    Dayton, Ohio 45417, United States
  • Daneshvari Solanki
    Houston, Texas 77004, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Memorial Hermann
    Houston, Texas 77089, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jan 2023, 20 months.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 20 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Mar 8, 2021
StartActual
Apr 14, 2021
Primary completionActual
Jan 10, 2023
CompletionActual
Jan 10, 2023
Last update
Feb 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04785638
Lead sponsor
Innocoll
Responsible party
Sponsor
First posted
Mar 8, 2021
Start date
Apr 14, 2021
Primary completion
Jan 10, 2023
Completion
Jan 10, 2023
Last update
Feb 13, 2023

Study contacts

Anne Arriaga
study director · Lotus Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion